Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
September 5, 2008

Agendia Offers Prognostic Tool for Breast Cancer

  • Agendia released TargetPrint®, a test that quantitatively determines the gene expression levels of the estrogen receptor, progesterone receptor, and HER2 in breast cancer tumor biopsies.

    TargetPrint runs on Agendia’s high-density chip, which received market clearance last month from the FDA

    “The test’s results give a precise molecular readout of prognostic parameters for breast cancer and provide physicians and patients with reliable guidance on the most suitable treatment for each individual patient,” says Richard A. Bender, M.D., CMO.

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: [email protected] An error has occurred. Please contact Customer Service at [email protected]
  • You’re all set! Thank you for subscribing to GEN Highlights.